Abstract: Topical dosages and formulations of chloroprocaine and pharmaceutically acceptable salts thereof are provided that are efficacious, chemically stable and physiologically balanced for safety and efficacy, particularly during ophthalmic procedures or in response to ophthalmic abrasions or trauma.

Abstract: Topical dosages and formulations of chloroprocaine and pharmaceutically acceptable salts thereof are provided that are efficacious, chemically stable and physiologically balanced for safety and efficacy, particularly during ophthalmic procedures or in response to ophthalmic abrasions or trauma.

Abstract: The invention concerns a process for producing a stable, injectable solution containing noradrenaline, comprising the following steps: (a) dissolving noradrenaline and optionally one or more excipients in deoxygenated or degassed water, in order to produce a solution containing noradrenaline; (b) distributing the noradrenaline solution in an inert gas current into a container; (c) sterilizing the solution containing, before step (b) and/or after step (d); (d) hermetically sealing the container; (e) wherein the oxygen concentration in the solution containing noradrenaline is less than 300 ppbw immediately after sealing the container; and (f) wherein the oxygen concentration in the headspace immediately after sealing the container is at most 1.0 percent v/v. It also concerns a drug product obtainable in particular by the above process, and the use of a gas atmosphere comprising an oxygen concentration of less than 1.0 percent v/v, as a headspace in a container comprising a solution containing noradrenaline.

Abstract: Methods of treatment, pharmaceutically acceptable solutions, and implantable devices are provided for the intrathecal treatment of AED-resistant seizures using levetiracetam.

Abstract: Sterile ophthalmic gels of chloroprocaine having improved functionality, pharmacokinetics, and stability, particularly in terms of clarity, and to methods of making and using same.

Abstract: Provided are ready to use drip bags of dilute noradrenaline having improved stability in terms of subvisible particle formation.

Abstract: Methods of treatment, pharmaceutically acceptable solutions, and implantable devices are provided for the intrathecal treatment of AED-resistant seizures using levetiracetam.

Abstract: Ready to use large volume containers of dilute solutions of phenylephrine having excellent shelf stability.

Abstract: Provided are ready to use drip bags of dilute noradrenaline having improved stability in terms of subvisible particle formation.

Abstract: Methods of treatment, pharmaceutically acceptable solutions, and implantable devices are provided for the intrathecal treatment of AED-resistant seizures using levetiracetam.

Abstract: Topical dosages and formulations of chloroprocaine and pharmaceutically acceptable salts thereof are provided that are efficacious, chemically stable and physiologically balanced for safety and efficacy, particularly during ophthalmic procedures or in response to ophthalmic abrasions or trauma.

Abstract: Topical dosages and formulations of chloroprocaine and pharmaceutically acceptable salts thereof are provided that are efficacious, chemically stable and physiologically balanced for safety and efficacy, particularly during ophthalmic procedures or in response to ophthalmic abrasions or trauma.

Abstract: Topical dosages and formulations of chloroprocaine and pharmaceutically acceptable salts thereof are provided that are efficacious, chemically stable and physiologically balanced for safety and efficacy, particularly during ophthalmic procedures or in response to ophthalmic abrasions or trauma.